You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
|
---|---|
Published in |
The Journal of Headache and Pain, October 2020
|
DOI | 10.1186/s10194-020-01186-3 |
Pubmed ID | |
Authors |
Stephen Silberstein, Merle Diamond, Nada A. Hindiyeh, David M. Biondi, Roger Cady, Joe Hirman, Brent Allan, Susan Pederson, Barbara Schaeffler, Jeff Smith |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 91 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 15 | 16% |
Student > Bachelor | 13 | 14% |
Other | 12 | 13% |
Student > Master | 6 | 7% |
Student > Postgraduate | 4 | 4% |
Other | 7 | 8% |
Unknown | 34 | 37% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 20 | 22% |
Neuroscience | 16 | 18% |
Pharmacology, Toxicology and Pharmaceutical Science | 10 | 11% |
Biochemistry, Genetics and Molecular Biology | 5 | 5% |
Nursing and Health Professions | 3 | 3% |
Other | 2 | 2% |
Unknown | 35 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 56. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 March 2023.
All research outputs
#686,776
of 23,849,058 outputs
Outputs from The Journal of Headache and Pain
#70
of 1,417 outputs
Outputs of similar age
#20,513
of 416,697 outputs
Outputs of similar age from The Journal of Headache and Pain
#4
of 30 outputs
Altmetric has tracked 23,849,058 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,417 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.6. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,697 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.